Recent Progress in the Development of mGluR4 Positive Allosteric Modulators for the Treatment of Parkinson's Disease

By  

Current Topics in Medicinal Chemistry, Vol. 9, Iss. 10, 2009-01 ,pp. : 949-963

Bentham Science Publishers

Access to resources Recommend Favorite

Metabotropic glutamate receptor 4 (mGlu₄)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature

By Lindsley Craig W   Hopkins Corey R  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 5, 2012-05 ,pp. : 461-481

Informa Healthcare

Access to resources Recommend Favorite

Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 4, 2014-06 ,pp. : 558-566

Bentham Science Publishers

Access to resources Recommend Favorite

mGluR2 positive allosteric modulators: a patent review (2009 – present)

By Trabanco Andrés A   Cid José María  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 5, 2013-05 ,pp. : 629-647

Informa Healthcare

Access to resources Recommend Favorite

Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 2 (mGluR2)

By  

Current Topics in Medicinal Chemistry, Vol. 5, Iss. 9, 2005-08 ,pp. : 869-884

Bentham Science Publishers

Access to resources Recommend Favorite